Evaluation of soluble concentration Fas and Fas ligand in maternal and cord blood 3rd trimester of pregnancy
Abstract
Objectives: The the study was to estimate the concentrations of antiapoptotic sFas and pro-apoptotic FasL in the serum of pregnant women in the third trimester of pregnancy and in the cord blood serum of neonates from vein and arteries separately. The correlation could be crucial for evaluation of apoptosis process intensity in placenta and the role of fetal blood circulation system on distribution of sFas and FasL. Material and methods: The study group consisted of 28 pregnant women in physiological pregnancy, between 38– 41 weeks. Vein blood was taken from maternal elbow vein and umbilical cord, separately from vein and arteries. The research was done by sets for sFas and FasL from R&D Systems Elisa kit. Results: In arterial and vein cord blood there were much more lower concentrations of sFas than in maternal blood-arterial cord blood 3351.78 pg/mL, vein cord blood 3351.78 pg/mL versus maternal blood 5769.62 pg/mL (p < 0.001). No difference was found in sFas concentrations between cord arterial and vein blood sera. Statistical difference was found between mean concentration of Fas ligand in maternal blood serum (71.36 pg/mL) and arterial cord blood serum (164.57 pg/mL) p < 0.05 (p = 0.001). Cord arterial blood serum showed much higher concentrations of FasL than maternal blood serum. No difference was found between cord arterial and vein blood sera concentrations of FasL: 164.57 pg/mL vs. 170.00 pg/mL (p = 0.701). Conclusions: Obtained results suggest no influence of sFas and FasL production on fetal organism apoptosis. Lowering of sFas concentration in fetal blood could mean the increase of apoptosis in fetal organism compared to maternal. Higher concentration of FasL in cord blood than in mothers suggests higher apoptosis intensification in fetal circulation and no influence of blood flow across placenta on its concentration.
Keywords: sFasFasLcord bloodpregnancy
References
- Diwanji N, Bergmann A. An unexpected friend - ROS in apoptosis-induced compensatory proliferation: Implications for regeneration and cancer. Semin Cell Dev Biol. 2017 [Epub ahead of print].
- Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014; 20(6): 607–615.
- Yamada A, Arakaki R, Saito M, et al. Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. Front Immunol. 2017; 8: 403.
- Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009; 30(2): 180–192.
- De Maria R, Testa U, Luchetti L, et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood. 1999; 93(3): 796–803.
- Peter ME, Hadji A, Murmann AE, et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 2015; 22(4): 549–559.
- Kim SK, Kim BK, Shim JH, et al. Nonylphenol and octylphenol-induced apoptosis in human embryonic stem cells is related to Fas-Fas ligand pathway. Toxicol Sci. 2006; 94(2): 310–321.
- Laskowska M, Laskowska K, Leszczyńska-Gorzelak B, et al. Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation. Eur J Obstet Gynecol Reprod Biol. 2006; 126(2): 155–159.
- Nagata S, Golstein P. The Fas death factor. Science. 1995; 267(5203): 1449–1456.
- Kuntz TB, Christensen RD, Stegner J, et al. Fas and Fas ligand expression in maternal blood and in umbilical cord blood in preeclampsia. Pediatr Res. 2001; 50(6): 743–749.
- Malamitsi-Puchner A, Sarandakou A, Papagianni V, et al. Concentrations of Soluble Fas in Maternal Serum and Amniotic Fluid During Uncomplicated Pregnancies. J Soc Gynecol Investig. 2003; 10(3): 158–160.
- Karthikeyan VJ, Lip GYH, Baghdadi S, et al. Soluble Fas and Fas ligand in pregnancy: influence of hypertension. Angiology. 2012; 63(1): 35–38.
- Vrachnis N, Dalainas I, Papoutsis D, et al. Soluble Fas and Fas-ligand levels in mid-trimester amniotic fluid and their associations with severe small for gestational age fetuses: a prospective observational study. J Reprod Immunol. 2013; 98(1-2): 39–44.
- Ashton SV, Whitley GS, Dash PR, et al. Uterine spiral artery remodeling involves endothelial apoptosis induced by extravillous trophoblasts through Fas/FasL interactions. Arterioscler Thromb Vasc Biol. 2005; 25(1): 102–108.
- Ishihara N, Matsuo H, Murakoshi H, et al. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol. 2002; 186(1): 158–166.
- Randhawa SR, Chahine BG, Lowery-Nordberg M, et al. Underexpression and overexpression of Fas and Fas ligand: a double-edged sword. Ann Allergy Asthma Immunol. 2010; 104(4): 286–292.
- Briana DD, Baka S, Boutsikou M, et al. Soluble fas antigen and soluble fas ligand in intrauterine growth restriction. Neonatology. 2010; 97(1): 31–35.
- Iwama H, Akutsu H, Kuretake S, et al. Serum concentrations of soluble Fas antigen and soluble Fas ligand in mother and newborn. Arch Gynecol Obstet. 2000; 263(3): 108–110.
- Bayram M, Taskaya A, Bagriacik EU, et al. The effect of maternal serum sFAS/sFASL system on etiopathogenesis of preeclampsia and severe preeclampsia. J Matern Fetal Neonatal Med. 2012 [Epub ahead of print].
